Search Results for "Sjogren A Belimumab"

14:19 EDT 28th July 2016 | BioPortfolio

Matching Channels


Matching News

Sjogren's Syndrome Foundation: Rheumatology Clinical Practice Guidelines Published

BETHESDA, MD--(Marketwired - Jul 22, 2016) - As we prepare to celebrate World Sjogren's Day on July 23 rd, the SSF is excited Read more...

Diquafosol Sodium in Dry-Eye Patients With Sjogren Syndrome

How does diquafosol sodium compare with artificial tears in terms of increasing aqueous tear volume in Sjogren's syndrome-associated dry eye? Eye

New study links cathepsin S protein to tear secretion in Sjogren's syndrome patients

The autoimmune disorder Sjogren's syndrome is often overlooked or misdiagnosed because the symptoms are similar to other conditions. Its characteristic symptoms are dry eyes and dry mouth, and reduced...

Human Genome Sciences and GlaxoSmithKline announce positive Phase 3 study results for Benlysta™ in systemic lupus erythematosus

Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced that Benlysta™ (belimumab, formerly LymphoStat-B®) met the primary endpoint in BLISS-52, the first o...

Regulatory update – BLA filed for Benlysta® (belimumab)

GlaxoSmithKline PLC (GSK) announced today that Human Genome Sciences, Inc. (HGS) has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), for Benlysta (belim...

Regulatory update - Benlysta® (belimumab)

GlaxoSmithKline PLC (GSK) announced today that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA), for Benlysta (belimumab) for reducing disease activi...

GlaxoSmithKline announces start of phase III study of Benlysta® (belimumab ) in patients with vasculitis

GSK today announced the start of a Phase III study to evaluate Benlysta® (belimumab) in patients with ANCA (Anti-neutrophil Cytoplasmic Antibodies) positive vasculitis - a condition that involves inf...

GlaxoSmithKline and Human Genome Sciences announce FDA priority review designation for Benlysta® (belimumab) as a potential treatment for systemic lupus erythematosus

GlaxoSmithKline PLC (GSK) and Human Genome Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted a priority review designation to Benlysta (belimumab) as a potent...

Matching PubMed Articles

A Retrospective Administrative Claims Database Evaluation of the Utilization of Belimumab in US Managed Care Settings.

Belimumab is an approved therapy for the treatment of systemic lupus erythematosus (SLE). This study examined the real-world utilization patterns of belimumab and standard SLE therapies in patients af...

Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjögren's syndrome: follow-up after the end of the phase II open-label BELISS study.

Belimumab, a monoclonal anti-B lymphocyte Stimulator (BLyS) antibody, appeared effective in Sjögren's syndrome (SS) in the phase II open-label 52-week BELISS study. Herein, the follow-up after the en...

Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness Analysis.

The purpose of this analysis is to evaluate the cost-effectiveness of belimumab, a new biological treatment specifically developed for the treatment of Systemic Lupus Erythematosus (SLE), in the Itali...

Secondary Sjogren's Syndrome in 83 Patients With Rheumatoid Arthritis.

Sjogren syndrome (SS) can occur alone, primary Sjogren syndrome, or in association with other rheumatic diseases, secondary Sjogren syndrome (sSS), such as Rheumatoid arthritis (RA). The occurrence of...

Rituximab-refractory lupus nephritis successfully treated with belimumab.


Search Whole site using Google

Quick Search
Advertisement Advertisement